{"id":"protein-subunit-novavax-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"35-45","effect":"Fatigue"},{"rate":"30-40","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Fever"},{"rate":"10-15","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant spike protein produced in insect cells, formulated into nanoparticles and combined with Matrix-M adjuvant to enhance immunogenicity. This stimulates both cellular and humoral immune responses, enabling the body to recognize and neutralize SARS-CoV-2 upon exposure. Unlike mRNA vaccines, this is a protein subunit approach that does not require integration into host cells.","oneSentence":"The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:12.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (primary series and booster doses)"}]},"trialDetails":[{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT06633835","phase":"PHASE4","title":"Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-09-20","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":660},{"nctId":"NCT05236491","phase":"PHASE2, PHASE3","title":"COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases","status":"UNKNOWN","sponsor":"Paul R Fortin","startDate":"2022-03-09","conditions":"Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus","enrollment":287}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["2024-25 COVID-19 vaccination"],"phase":"marketed","status":"active","brandName":"protein subunit: Novavax COVID-19 vaccine","genericName":"protein subunit: Novavax COVID-19 vaccine","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus. Used for COVID-19 prevention in adults (primary series and booster doses).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}